



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/601,644

12/11/2000

Jean Garipey

MMC.P-001

7797

57381 7590 05/14/2008

Marina Larson & Associates, LLC

P.O. BOX 4928

DILLON, CO 80435

EXAMINER

SHIBUYA, MARK LANCE

ART UNIT

PAPER NUMBER

1639

MAIL DATE

DELIVERY MODE

05/14/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Application Number: 09/601,644
Filing Date: December 11, 2000
Appellant(s): GARIEPY ET AL.

MARINA T. LARSON, PH.D.
For Appellant

EXAMINER'S ANSWER

This is in response to the appeal brief filed 2/11/2008 appealing from the Office action mailed 7/12/2007.

(1) Real Party in Interest

A statement identifying by name the real party in interest is contained in the brief.

(2) Related Appeals and Interferences

The examiner is not aware of any related appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

(3) Status of Claims

The statement of the status of claims contained in the brief is incorrect. A correct statement of the status of the claims is as follows:

This appeal involves claims 1-7, 9-16, 18, 20, 27-29, 32, 33, 37-41 and 43.

Claims 17, 24 and 25 are withdrawn from consideration as not directed to the elected Invention.

Claims 8, 19, 21, 22, 23, 26, 30, 31, 34-36 and 42 have been canceled.

(4) Status of Amendments After Final

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

(5) Summary of Claimed Subject Matter

The summary of claimed subject matter contained in the brief is correct.

(6) Grounds of Rejection to be Reviewed on Appeal

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

(7) Claims Appendix

The copy of the appealed claims contained in the Appendix to the brief is correct.

(8) Evidence Relied Upon

6833131	SMITH	12-2004
20020161203	SHEPPARD	10-2002
20030188326	D'ANDREA	10-2003

Hartley et al., Cytotoxic Ribosome-Inactivating Lectins from Plants, Review, Biochimica et Biophysica Acta (2004), 1701, pp. 1-14

Roberts et al., Ribosome-Inactivating Proteins: Entry into Mammalian Cells and Intracellular Routing, Mini Reviews in Medicinal Chemistry (2004) Vol. 4, pp. 505-512.

Battelli, Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins, Mini Reviews in Medicinal Chemistry (2004) Vol. 4, pp. 513-521

Kaneda, "Gene Therapy: A Battle Against Biological Barriers", Current Molecular Medicine 2001, Vol. 1, pp. 493-499.

Examination Guidelines on Written Description (uspto.gov/web/menu/written.pdf).

(9) Grounds of Rejection

The following ground(s) of rejection are applicable to the appealed claims:

Claims 1-7, 9-16, 18, 20, 27-29, 32, 33, 37-41 and 43 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in

such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is for lack of written description.

Vas-Cath Inc. v. Mahurkar, 19 USPQ 2d 1111, clearly states “Appellant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See Vas-Cath at page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 116).

The claimed genus of cytotoxic proteins is broad and includes species named in the specification and claimed, such as Shiga toxin, Shiga-like toxins, ricin, abrin, gelonin, croton, pokeweed antiviral protein, saporin, momordin, modeccin, sarcin, diphtheria toxin and *Pseudomonas aeruginosa* exotoxin A, as well as other species not described, such as snake, lizard, spider and insect venoms (see, e.g., US Patent No. 6,833,131 at col. 1, lines 10-35; US Publication No. 2002/0161203 A1 at para [0005], [0190]). The specification provides specific embodiments, working or otherwise, only for Shiga-toxin and Shiga-like toxins. In the Specification, at Example 4, pp. 22-23, the method used for producing a cytotoxic mutant protein having a different receptor-binding specificity than the wild type protein appears to rely on using the CAMA-I cell line, because it lacks the CD77 marker that is the receptor for Shiga toxin and Shiga-like toxin (p. 12, lines 16-19). The specification does not disclose cell lines that similarly lack the receptors for the other heteromeric protein toxins that constitute the genus.

The examiner respectfully submits that the specification does not provide a representative number of species to show possession over the entire genus claimed. It is noted that the examined claims do not require that the screening cell line lack the receptor recognized by the wild-type toxin.

The specification at p. 25, lines 25-29, states that the "B subunit variants may thus bind to a spectrum of molecular entities such as proteins, peptides, nucleic acids or even organic moieties rather than to sugars or glycolipids (such as CD77)." However, in regard to the embodied species of Shiga-toxin, the specification does not describe what different receptor the mutated B subunit now has specificity for and describes no assays, actual or prophetic, to demonstrate positively that the mutated toxins now have specificity for a different receptor, as claimed. Also, the specification does not disclose that the mutated B subunits do not bind to the CD77; rather that the mutated toxin kills CAMA-1 cells, which the specification teaches lacks CD77, and SKBR-3 cells, which the specification teaches expresses CD77 (Specification at p. 22, lines 4-14). Given the unpredictability of the arts of biology and of mutation, particularly in changing the target of a protein ligand, extrapolation from cytotoxicity data (see Specification at Example 4, pp. 22-23) that the mutated Shiga toxin B subunit has a different receptor-binding specificity is uncertain. The Office does not have the facilities and resources to provide the factual evidence needed in order to determine that the cytotoxic mutant protein has a different receptor-binding specificity than the wild type protein. It is respectfully submitted that the practitioner would not be reasonably apprised that the Appellant was

in possession of the claimed invention, in regard to the particular species of Shiga toxin or Shiga-like toxin.

Vas-Cath Inc. v. Mahurkar, 19 USPQ 2d 1111, clearly states “Appellant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed*.” (See Vas-Cath at page 1117). See, also, Fiers v. Revel, 25 USPQ 2d 1601 at 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. One cannot describe what one has not conceived. See Fiddes v. Baird, 30 USPQ2d 1481 at 1483. In Fiddes, claims directed to mammalian FGF’s were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence. Appellant is reminded that Vas-Cath makes clear that the written description provision of 35 § 112 is severable from its enablement provision.

Response to Arguments, Mailed 2/27/2006

The Appellant argues that amending the claims to recite that the heteromeric protein toxins are ribosome-inactivating protein (RIP) overcomes the instant written description because RIPs are described in the specification and include the Shiga and Shiga-like toxins. The Appellant argues that the two breast cancer cell lines described in the specification is representative of the genus of screening cells because the particular cell type used in the claimed method is not critical, provided the combination of toxin and cell type are such that a selection can be made based on an observed increase in toxicity. Appellant argues that an important benefit of the present invention

is that it does not require any prior or subsequent knowledge of the specific nature of the receptor. Appellant states:

The screening technique identifies, via observed toxicity, the mutation that works in combination with some receptor on the screening cells, and neither the nature of the receptor nor the nature of the mutation needs to be known. While it may be interesting to know the type of receptor a new toxin binds to, this is not a reason to say that there is no written description of the invention as claimed.

Reply at p. 11, para 2.

Appellant's arguments entered, 11/21/2005, have been fully considered but they are not persuasive.

The specification does not provide a representative number of species to show possession over the entire genus of RIP claimed. Heteromeric RIP, as claimed, appear to represent type 2 RIP. The genus of type 2 RIPs include certain plant toxins, such as the lectin ricin, and bacterial toxins, including Shiga toxin and Shiga-like toxin, produced by enterohemorrhagic strains of *Escherichia coli*, as well as other toxins (see Hartley et al., *Biochimica et Biophysica Acta* (2004), 1701, pp. 1-14, and especially p. 2, para 3 and Table 1). The specification as filed includes some of these type 2 RIPs, such as ricin, abrin, momordin, shiga toxin and shiga-like toxin, but does not disclose others, such as volkensin, viscumin, ebulin b, SNAI, SNAV, or SNAIf.

The claims are drawn to selecting mutant proteins with a different binding specificity than the wild type binding protein. Appellant bases this element on the use of the CAMA-1 cell line, which appears to lack the CD77 glycolipid, to which the Shiga toxin and Shiga-like toxin bind, (as taught by the instant specification). It appears that Appellant reasons that because the CAMA-1 cell line lacks the CD77 receptor, the

mutated toxins must act by having a different receptor binding specificity, i.e., binding to a different receptor. However, the specification does not describe species of cell lines that lack the receptors for different species of the genus of RIPs, other than the CAMA-1 cell line, which is specific for Shiga toxin or Shiga like toxin. For example, there are no described cell lines that are resistant to volkensin, viscumin, ebulin b, SNAI, SNAV, or SNAIf.

The practitioner would not envision that the Appellant had process of mutant proteins that have different receptor specificity. Appellant has not identified what receptor the mutated Shiga toxin or Shiga-like toxin binds to and therefore, the specification cannot describe it. Roberts et al., *Mini Reviews in Medicinal Chemistry* (2004) Vol. 4, pp. 505-512, throughout the publication, and e.g., at p. 507, para 2, teach that the RIP ricin, is taken into the cell by endocytosis after binding galactosides on the mammalian cell surface. Roberts et al. states “[t]he precise endocytic route may be influenced by the nature of the surface molecule to which the toxin has bound, and since ricin promiscuously binds to many different surface glycoproteins, it isn’t perhaps surprising to find that it can enter by both clathrin-dependent and clathrin-independent endocytosis.” Thus the RIP and its mutant protein may have common specificity to one or more of several different receptors. Perhaps a mutant RIP continues to have the same receptor binding specificity, but other pathways are affected or different.

The publication of Battelli, *Mini Reviews in Medicinal Chemistry* (2004) Vol. 4, pp. 513-521, throughout the publication, and e.g., at p. 513, bridging paragraph and p. 513, para 2, teaches that “[c]omparing the cytotoxicity of various type 2 RIP for a cell line

and, conversely, the different sensitivity of various cell lines to the same toxin, it appeared clear that the interaction between cells and RIP was more complicated than it was predictable on the basis of the molecular structure.” Battelli states that “[t]he correlation between RIP structure and cytotoxicity had become even less linear when a new category of type 2 RIP emerged, which, in spite of the presence of the lectinic chain, have a low toxicity, similar to that of type 1 RIP (Table 1). . . . For instance, the lower cytotoxicity of nigrin b compared with ricin has been at least in part explained by a higher degradation of nigrin b by cells, with a resulting lower concentration remaining inside the cells, and by the different intracellular pathways followed by the two lectins”. Thus it is clear that the genus of RIPs is heterogeneous, unpredictable, and complicated in the mechanism of action. Therefore, one of skill in the art would not envision that the Appellant had possession of the invention as now claimed.

Furthermore, in regard to newly examined claims, drawn to methods of making probes and medicaments, the specification does not provide guidance and direction for detecting or treating disease, *in vivo*.

In regard to said methods of making medicaments, it is respectfully noted that the instant claims read upon vectors for gene therapy, which is an unpredictable art. In particular, sufficient delivery to and expression in target tissues is not predictable. Kaneda, “Gene Therapy: A Battle Against Biological Barriers”, Current Molecular Medicine 2001, Vol. 1, pp. 493-499, throughout the publication and abstract, teaches that successful gene therapy is dependent on the development of an effective gene delivery system. Kaneda teaches that gene therapy continues to be stymied by problems

in targeting, permanence and quantity of expression of the gene in question, immunogenicity, etc. Kaneda notes that various gene delivery systems, including adenovirus systems, have well known limitations that have prevented safe and successful methods of gene therapy.

Response to Arguments, mailed 11/20/2006

Appellant argues that improperly, the examiner has not looked at the “particular invention” as claimed to determine if written description exists, (citing *Capon v. Eshar*, 76 USPQ2d 1078 (Fed. Cir. 2005)). Appellant argues that because the specification disclosed the generic name of ribosome inactivating proteins and a number of examples, a person skilled in the art would know, unequivocally, that appellant understood the invention to include toxins within this genus at the time the invention was filed. Appellant argues that the examiner’s allegation that the lack of additional cell lines suitable for use with toxins other than Shiga or Shiga-like toxin (i.e., the CAMA-1 cell line), focuses too narrowly on the elements and not on the claimed invention because the method, (whose purpose is to allow development of binding portions) can be applied to cells different from CAMA-1. Appellant argues that the alleged lack of possession of mutant proteins that have different receptor binding specificity is not relevant, as Appellant are claiming a method of identifying proteins, (directing the examiner’s attention to Examples 10 and 18 of the Examination Guidelines on Written Description (uspto.gov/web/menu/written.pdf)). Appellant argues that others may use the claimed method, including the key screening step, in the future to make additional proteins not specifically disclosed, and that to deny patent protection to the Appellant

against such use is improper, (directing the examiner's attention to *In re Fuetterer*, 319 F.2d 259, 138 USPQ 217 (CCPA 1963).

Appellant's arguments entered, 6/27/2006, have been fully considered but they are not persuasive.

The specification does not provide description for the full scope of making cytotoxic mutant proteins for any heteromeric ribosome inactivating protein toxin because the specification does not describe the nucleic acid sequences for ribosome inactivating proteins and does not provide cell lines that are insensitive to ribosome inactivating protein toxins, except for Shiga toxin and Shiga-like toxin. Furthermore, the specification does not point to where in the art, at the time of filing (1998), these elements could be found. The specification as filed does not describe that the sequences for the heteromeric ribosome inactivating proteins were known; and the specification does not describe cell lines insensitive to the heteromeric ribosome inactivating proteins, other than CAMA-1, (which is insensitive to Shiga toxin and Shiga-like toxin). The examiner submits that one of skill in the art would not know what cells to substitute for CAMA-1. Absent evidence to the contrary, these gene sequences and cell lines would have to be created *de novo*, before the claimed method could be practiced in its full scope. Therefore, one of skill in the art would not envision that Appellant had possession of the claimed method drawn to making a cytotoxic mutant protein that is any heteromeric ribosome inactivating protein.

The nature of the receptor is relevant to enablement of the claimed invention; at least because the amended claim states that the mutated proteins have a "receptor-

binding specificity for a receptor that is different from the receptor to which the wild type protein has receptor binding specificity". Without recognition of the nature of the receptor to which the mutated protein binds, one of skill in the art would not be reasonably apprised that the receptor was different, as required by the claims. It is respectfully noted that one of skill in the art would appreciate that insensitivity to a toxin might result from a variety of reasons, such as amplification of the gene of a target protein or an enhanced toxin efflux mechanism in the insensitive cell, (*compare*, D'Andrea, U.S. 2003/0188326, at para 71, discussing various possible causes for drug resistance).

In regard to conformance with Examples 10 of the Examination Guidelines on Written Description, the examiner respectfully notes that Example 10 contemplates claims drawn to a method for isolating polynucleotide comprising hybridizing a specific sequence, as denoted by a sequence identifier, which is different from the instant claims, which do not provide nucleotide sequences for the genus of ribosome inactivating proteins. Furthermore, the examiner respectfully submits that the specification does not indicate where to find sequences of that genus in the prior art.

In regard to Example 18, the examiner respectfully notes that Example 18 contemplates that the art teaches that a particular nucleic acid is not essential to the claimed method of producing a protein of interest in *Neurospora*, which is a different circumstance from the instant claims, because each of the different heteromeric ribosome inactivating protein mutants would require a corresponding cell line that was insensitive to that heteromeric ribosome inactivating protein. Absent evidence to the

contrary, one of skill the art would not know whether such insensitive cell lines exist, except for the single example of the CAMA-1 cell line.

In regard to Appellant's argument that others may use the claimed method, including the key screening step, in the future to make additional proteins not specifically disclosed, and that to deny patent protection to the Appellant against such use is improper (citing *In re Fuetterer*), the examiner respectfully submits that the unlike the different inorganic salts of *In re Fuetterer*, which served merely to maintain carbohydrates or proteins in a colloidal suspension simply by virtue of being a salt, each individual and different heteromeric ribosome inactivating protein and its corresponding insensitive cell line, cannot stand in the place of the other heteromeric ribosome inactivating proteins and their corresponding insensitive cell line. That is to say, having the CAMA-1 cell line, which is insensitive to Shiga toxin and Shiga-like toxin, does not convey possession for mutants of other ribosome inactivating proteins which have specificity for a receptor that is different from the receptor to which the wild type protein has receptor binding specificity, because of unpredictability of the molecular biology of ribosomal inactivating proteins, as taught by Battelli, (of record).

Response to Arguments, mailed 7/12/2007

Appellant argues that recitations of known nucleic acid/amino acid sequences are not required for written description. Appellant's point to exemplary documents in Exhibit A. Appellant argues that the claimed invention is generally applicable, and so no creation of a cell line is required, just the existence of cells that are of interest.

Appellant argues that what is claimed is a method for finding of combinations of ribosome inactivating proteins (RIP) and insensitive cell lines.

Appellant's arguments, entered 4/9/2007, have been fully considered but they are not persuasive. The examiner respectfully submits that the exemplary documents provided do not indicate that representative nucleic acid/amino acid sequences are known for the genus of ribosome inactivating proteins. Appellant does not point to a consensus sequence for the genus of ribosome inactivating proteins.

The examiner respectfully submits that the creation of the resistant cell lines is required; and that it is unclear that cells of interest useful for practicing the full scope of claimed invention in fact exist.

The examiner respectfully submits that resistant cells are first required to practice the claimed invention.

Claims 1-7, 9-16, 18, 20, 27-29, 32, 33, 37-41 and 43 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods of for making a cytotoxic mutant protein or pool of Shiga toxin or Shiga-like toxin proteins, does not reasonably provide **enablement** for making mutants for any heteromeric ribosome inactivating protein with a different receptor binding specificity. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. This rejection is necessitated by Appellant's amendments to the claims.

This rejection is maintained for the reasons of record as set forth in the previous Office action in the rejection of claims 1-7, 9-16, 42 and 43. That rejection is copied below for the convenience of the reader. The new grounds of rejection are in response to the examination of previously withdrawn claims.

There are many factors be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether undue experiment is necessitated. These factors can include, but are not limited to:

- (1) the breadth of the claims;
- (2) the nature of the invention;
- (3) the state of the prior art;
- (4) the relative skill of those in the art;
- (5) the level of predictability in the art;
- (6) the amount of direction provided by the inventor;
- (7) the existence of working examples; and
- (8) the quantity of experimentation needed to make or use the invention based on the content of the disclosure.

In re Wands, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

(1 and 2) The breadth of the claims and the nature of the invention: The claims are drawn to a method for making a cytotoxic mutant protein that is a ribosome inactivating protein,(RIP), having a receptor-binding specificity that is different from the specificity of the wild type RIP, comprising incorporating mutations into DNA encoding the binding domain of a heteromeric RIP toxin to produce variant forms of the heteromeric RIP toxin, generating a library of clones to produce variant forms of the heteromeric RIP toxin, screening against a population of screening cells and selecting a cytotoxic mutant protein that inhibits or kills said population of screening cells to a

greater extent than wild-type cytotoxic mutant protein. Thus the claim is broadly drawn to making mutants of any heteromeric RIP toxin. The specification at p. 25, , lines 25-29, states that the "B subunit variants may thus bind to a spectrum of molecular entities such as proteins, peptides, nucleic acids or even organic moieties rather than to sugars or glycolipids (such as CD77)." Therefore, the different receptor to which the variant forms of the mutated cytotoxic protein can bind, is contemplated by the specification to encompass virtually any biological molecule.

(3 and 5) The amount of direction provided by the inventor and the existence of working examples: Appellants have only exemplified the preparation of mutant Shiga toxin, although the example probably is applicable to Shiga-like Toxin-1, as the specification at p. 12, lines 16-19 teaches that both toxins recognize the glycolipid CD77 (also known as Gb₃). In Example 4, pp. 22-23, the specification provides specific embodiments, working or otherwise, only for method used for producing a cytotoxic mutant protein of Shiga-toxin. However, in regard to the embodied species of Shiga-toxin, the specification does not describe what different receptor the mutated B subunit now has specificity for and describes no assays, actual or prophetic, to demonstrate positively that the mutated toxins now have specificity for a different receptor, as claimed. The specification does not disclose the molecule, if any, to which the mutated B subunit of the variant Shiga toxin protein now binds. Also, the specification does not disclose that the mutated B subunits do not bind to the CD77; rather that the mutated toxin kills CAMA-1 cells, which the specification teaches lacks CD77, and SKBR-3 cells, which the specification teaches expresses CD77 (Specification at p. 22, lines 4-14).

The specification does not provide guidance or direction for cell lines resistant to RIP other than Shiga toxin or Shiga-like toxin.

Furthermore, in regard to newly examined claims, drawn to methods of making probes and medicaments, the specification does not provide guidance and direction for detecting or treating disease, *in vivo*.

(4) The state of the prior art and the level of predictability in the art Methods for making for making mutant Shiga toxin and mutant Shiga-like toxin was known in the art at the time of filing, however, the correlation of RIP receptor specificity to RIP-induced cytotoxicity is unpredictable. The publication of Battelli, Mini Reviews in Medicinal Chemistry (2004) Vol. 4, pp. 513-521, throughout the publication, and e.g., at p. 513, bridging paragraph and p. 513, para 2, teaches that “[c]omparing the cytotoxicity of various type 2 RIP for a cell line and, conversely, the different sensitivity of various cell lines to the same toxin, it appeared clear that the interaction between cells and RIP was more complicated than it was predictable on the basis of the molecular structure.” Battelli states that “[t]he correlation between RIP structure and cytotoxicity had become even less linear when a new category of type 2 RIP emerged, which, in spite of the presence of the lectinic chain, have a low toxicity, similar to that of type 1 RIP (Table 1). . . . For instance, the lower cytotoxicity of nigrin b compared with ricin has been at least in part explained by a higher degradation of nigrin b by cells, with a resulting lower concentration remaining inside the cells, and by the different intracellular pathways followed by the two lectins”. Thus it is clear that the genus of RIPs is heterogeneous, unpredictable, and complicated in the mechanism of action. Appellant’s claimed scope

of any heteromeric RIP toxin, such that mutations thereto that result in changed receptor specificity from that of wild type toxin, and such that a population of screening cells would be killed or inhibited to a greater degree, than by the wild type toxin, represent only an invitation to experiment with the genus of RIP (see also above concerning written description and references and cases cited therein). In view of the uncertainty in the art, extrapolation from cytotoxicity data (see Specification at Example 4, pp. 22-23) that a mutated RIP has a different receptor-binding specificity is unpredictable.

In regard to newly examined claims, drawn to methods of making probes and medicaments, the specification does not provide guidance and direction for detecting or treating of any disease is unpredictable.

In regard to said methods of making medicaments, it is respectfully noted that the instant claims read upon vectors for gene therapy, which is an unpredictable art. In particular, sufficient delivery to and expression in target tissues is not predictable. Kaneda, "Gene Therapy: A Battle Against Biological Barriers", Current Molecular Medicine 2001, Vol. 1, pp. 493-499, throughout the publication and abstract, teaches that successful gene therapy is dependent on the development of an effective gene delivery system. Kaneda teaches that gene therapy continues to be stymied by problems in targeting, permanence and quantity of expression of the gene in question, immunogenicity, etc. Kaneda notes that various gene delivery systems, including adenovirus systems, have well known limitations that have prevented safe and successful methods of gene therapy.

(6-7) The level of one or ordinary skill: The level of skill would be high, most likely at the Ph.D. level. However, such persons of ordinary skill in this art, *given its unpredictability*, would have to engage in undue (non-routine) experimentation to carry out the invention as claimed.

(8) The quantity of experimentation needed to make or use the invention based on the content of the disclosure: The claims contain only broad recitations of “heteromeric protein toxin that is a ribosome inactivation protein” and mutant variant protein toxins having “a different receptor-binding specificity”. However, the instant specification does not provide to one skilled in the art a reasonable amount of guidance with respect to the direction in which the experimentation should proceed in carrying out the full scope of the claimed methods. Note that there must be sufficient disclosure, either through illustrative examples or terminology, to teach those of ordinary skill how to make and use the invention as broadly as it is claimed. *In re Vaeck*, 947 F.2d 488, 496 and n.23, 20 USPQ2d 1438, 1455 and n.23 (Fed. Cir. 1991). Therefore, it is deemed that further research of an unpredictable nature would be necessary to make or use the invention as claimed. Thus, due to the inadequacies of the instant disclosure, undue experimentation would be required of one of ordinary skill in the art to practice the full scope of the claimed invention.

Response to Arguments, mailed 11/20/2006

Appellant argues that the examiner has not stated why one of skill in the art would require undue experimentation to make mutations of any heteromeric RIP toxin. Appellant argues that because the claims require no recognition of the nature of the

different receptor, there is no explanation of why this breadth has anything to do with undue experimentation. Appellant argues that the examiner has not provided a reason why undue experimentation would be required for any of the steps of the claimed invention.

Appellant's arguments entered, 6/27/2006, have been fully considered but they are not persuasive.

As set forth in the previous Office action, undue experimentation would be required of one of skill in the art because the instant specification does not provide to one skilled in the art a reasonable amount of guidance with respect to the direction in which the experimentation should proceed in carrying out the full scope of the claimed methods. The specification does not provide guidance and direction for the full scope of making cytotoxic mutant proteins for any heteromeric ribosome inactivating protein toxin because the specification does not provide the nucleic acid sequences for ribosome inactivating proteins and does not provide cell lines that are insensitive to ribosome inactivating protein toxins, except for Shiga toxin and Shiga-like toxin. Furthermore, the specification does not point to where in the prior art, at the time of filing (1998), these gene sequences and cell lines could be found. Therefore, the specification as filed does not provide guidance and direction as to whether the sequences for the heteromeric ribosome inactivating proteins were known; and the practitioner would not be provided guidance and direction for employing cell lines insensitive to the heteromeric ribosome inactivating proteins in the claimed method. Absent evidence to the contrary, one of skill in the art would have to create these elements, before the

claimed method could be made and used in its full scope. However, the specification as filed does not provide guidance and direction for the obtaining of the gene sequences or the making of appropriately insensitive cell lines. Thus the claimed invention does not merely require routine screening, but would require undue experimentation to make and use.

The nature of the receptor is relevant to enablement of the claimed invention, at least because the amended claim states that the mutated proteins have a “receptor-binding specificity for a receptor that is different from the receptor to which the wild type protein has receptor binding specificity”. Without recognition of the nature of the receptor to which the mutated protein binds, it is not clear that the receptor is different, as required by the claims. It is noted that one of skill in the art would appreciate that insensitivity to a toxin might result from a variety of reasons, such as amplification of the gene of a target protein or an enhanced toxin efflux mechanism in the insensitive cell, (*compare*, D'Andrea, U.S. 2003/0188326, at para 71, discussing various possible causes for drug resistance).

Because these elements are required to practice the claimed method, their absence would require undue experimentation for one of skill in the art.

Response to Arguments, mailed 7/12/2007

Appellant argues that the examiner does not indicate why a practitioner would have difficulty practicing the claimed invention. Appellant argues that amendments to claim 1 clarify that because target cells are initially insensitive, therefore the receptor binding specificity must have changed. Appellant argues that the claimed method of

making medicaments does not require the use of gene therapy to work. Appellant argues that the claimed method actually enables gene therapy, by addressing the problem of targeting.

Appellant's arguments, entered 4/9/2007, have been fully considered but they are not persuasive. The examiner respectfully submits that it would be unpredictable to produce insensitive cells to any ribosome inactivating protein toxin. The examiner respectfully argues that it is possible for insensitive cells to become resistant, even though the receptor binding specificity remains the same. The examiner respectfully submits that claims must be given their broadest reasonable interpretation, consistent with the specification, so that the claimed method of making medicaments encompasses gene therapy. The examiner respectfully submits that it is unclear that claimed method enables gene therapy.

(10) Response to Argument

Appellant argues the rejections are based on the examiner's failure to understand the invention and both appropriateness of the disclosure to that invention. Appellant argues that this issue is common to both issues. Appellant describes an RIP protein and its binding and toxic domain subunits. Appellant states that for the toxic subunit or domain to be toxic to a cell, that cell must have a receptor to which the binding domain binds. Appellant states in the method the selected protein to be mutated and selected and the cells to be tested in the assay "have certain properties in relationship to one another, namely the cells are insensitive to the unmutated toxin at the levels used in the

test”, (Brief at p.3). Applicant argues that “[s]ince toxicity only occurs when the binding domain BD recognizes and interacts with a receptor on the cell, it follows logically that the variant that produces toxicity must now have a binding domain that has a different specificity than the unmutated RIP protein and that this different specificity is one that recognizes a receptor on the cells used in the test. To perform this test, it is not necessary to know what the receptor on the target cells is, nor to design a binding domain to match it.” Brief at p. 3-4, bridging paragraph.

Finally, in explaining the invention, appellant states:

For real world application, **the starting point of the assay** will be a selection of cells for which a binding domain is desired. These cells are then tested against RIPs to identify one or more wild type RIPs to which the cells are insensitive. These are the RIP proteins that are initially selected and utilized to generate binding domain mutants for further testing.

Brief at p. 4, (emphasis added).

Appellant's explanations of the nature of invention, entered 2/11/2008, have been fully considered but the examiner respectfully submits that they are not persuasive to overcome the standing rejections under appeal, because they obscure the interpretation of the claims.

The examiner does not find, as a claimed limitation, the step of testing cells to find those that are insensitive to the wild-type toxin. In fact the claim is drawn to screening cells that already are insensitive to the genus of ribosome inactivating protein (RIP) toxins. Appellant does not indicate where the specification teaches this selection of insensitive cells, which appellant states is the starting point of the assay, and that dictates the choice of RIP protein are to be mutated.

The examiner respectfully submits that the claimed invention encompasses genera of prophetic binding domain variants of unspecified RIP proteins, which are selected by prophetic functional cytotoxicity assays, and that bind to totally unknown receptors.

In regard to appellant's assertion that "it follows logically that the variant that produces toxicity must now have a binding domain that has a different specificity than the unmutated RIP protein and that this different specificity is one that recognizes a receptor on the cells used in the test", the examiner respectfully submits that this substitutes argument, in the form of an asserted logical necessity, for evidence, in an unpredictable art. As discussed, *supra*, cellular toxin resistance may have a number of possible etiologies.

Rejection for Lack of Written Description

Appellant argues that there is no absolute requirement for an exhaustive recapitulation of known sequences, (Brief at p. 5). Appellant states that commonality in sequence across the genus of ribosome-inactivating proteins plainly does not exist. Appellant states that "[t]he genus of RIPs is defined in the art by functional characteristics, and RIPs can come from various sources and have different native toxicity based on the receptor to which they bind", (Brief at p. 5).

Appellant argues the selected cell line is that for which a binding entity is desired, such as a tumor cell of a particular type or from a particular patient. The applicant argues that there is no requirement to know what structures are present on the cell,

because cytotoxicity indicates that the mutant has bound to whatever receptor is present. Thus, the specification clearly provides that the invention applies to cells generally.

Appellant argues that the resistant cell lines do not need to be created as these cells already exist.

Appellant's arguments, entered 2/11/2008, have been fully considered but the examiner respectfully submits that these arguments are not persuasive. Appellant appears to assert that the sequences of the members of the genus of RIP are known in the art. This assertion is inferred to be evidenced by the publication exhibits in the instant Evidence Appendix. However, it is unclear that these publications provide evidence that the sequences of the genus of RIP are known, as would be commensurate with the claims.

Furthermore, the examiner respectfully submits that each individual and different heteromeric ribosome inactivating protein and its corresponding insensitive cell line, cannot stand in the place of the other heteromeric ribosome inactivating proteins and their corresponding insensitive cell line. For example, having the CAMA-1 cell line, which apparently is insensitive to Shiga toxin and Shiga-like toxin, does not convey possession for mutants other ribosome inactivating proteins which have specificity for a receptor that is different from the receptor to which the wild type protein has receptor binding specificity, because commonality in sequence across the genus of ribosome-inactivating proteins plainly does not exist. Furthermore, the biology of ribosomal inactivating proteins is not predictable, as taught by Battelli, (of record).

The examiner respectfully notes that the claims are drawn to using cells that are insensitive to a selected RIP toxin protein. However, the specification as filed does not appear to indicate any insensitive cells other than CAMA-1 cells. Appellant does not point to where in the prior art, other RIP-insensitive cell lines are taught. Appellant does not indicate that the CAMA-1 cells would be resistant to RIP toxins other than Shiga toxin and Shiga-like toxin. In fact, appellant appears to argue that the sequences of these toxins are unrelated to other RIP toxins and that they would therefore target different receptors.

Appellant argues that because claim 10 is drawn to Shiga toxin and Shiga-like toxin 1, that only the argument that the CAMA-1 cell line teaching is insufficient for the describing the genus of RIP-insensitive cell lines is applicable. The examiner respectfully submits an argument toward the lack of possession of the genus of insensitive cell lines is, indeed, appropriate. Furthermore, the examiner again notes that the appellant does not describe what receptor the mutated domain is now binding, and so one of skill would not envision that appellant possessed a receptor that is different from the receptor to which the wild type protein has receptor specificity, as stated in the claims.

Appellant argues that because claim 15 specifies the CAMA-1 cell line, that the invention of claim 15 is described. The examiner respectfully notes that the claim is drawn to the genus of RIP toxins, and that there is no indicia of predictability that the CAMA-1 cell line is insensitive to RIP toxins other than Shiga and Shiga-like toxins. Appellant's argument that the RIP toxins are defined functionally and are not structurally

related by sequence may be thought to argue that possession of one RIP toxin does not confer possession of the others.

Rejection for Lack of Scope of Enablement

Appellant argues that claim 1 is, itself, essentially the instructions for performing the method of the invention, (Brief at p. 8). Appellant argues that the protein and the cells are chosen in combination so that the cells are insensitive to the wild type protein at the concentration used in screening and that if toxin sensitivity for a cell type is not already known, simply screening the cells against RIP toxins to find one that does not kill the cells would establish the pairing of cells and toxins to use. Appellant argues that if the *cells* are insensitive to toxin through some other mechanism than the failure to bind, they will not suddenly become sensitive through mutation of the *toxin's* binding domain, i.e. with no change to the cell.

Appellant's arguments, entered 2/11/2008, have been fully considered but the examiner respectfully submits that these arguments are not persuasive. Claim 1 does not provide instruction on how to obtain the genus of cells that are *insensitive* to the various, unrelated RIP toxins. Rather, claim 1 presumes these insensitive cells to be at hand, already. Appellant's argument in the brief that simply screening any cells against RIP toxins will produce cells insensitive to RIP toxins is not supported by any proffered objective evidence and appears to be mere attorney argument.

It is noted that one of skill in the art would appreciate that insensitivity to a toxin might result from a variety of reasons, such as amplification of the gene of a target

protein or an enhanced toxin efflux mechanism in the insensitive cell, (*compare*, D'Andrea, U.S. 2003/0188326, at para 71, discussing various possible causes for drug resistance). Thus the examiner respectfully argues that the impossibility of insensitive cells to become sensitive, even though the receptor binding specificity remains the same, has not been established by scientific evidence.

Appellant's argument in the brief that if the cells are insensitive to toxin through some other mechanism than the failure to bind, it will not suddenly become sensitive through mutation of the toxin's binding domain, i.e. with no change to the cell, has not supported by the furnishing of objective evidence and appears to be mere attorney argument. For example, the mutated binding domain might bind to a different epitope on the receptor.

Appellant argues in regards to claim 32 and 33 that the combination of the medicament portion and the binding portion that is formed in accordance with claim 32 can be used by administration of the protein directly and need not involve gene therapy. The examiner respectfully submits that this is not persuasive because claim 33, which depends from claim 32, is drawn to preparing a medicament DNA sequence and a binding domain or subunit DNA sequence encoding the binding portion, further comprising the step of expressing the medicament DNA sequence. The examiner respectfully submits that claim 32, which is drawn to making a target medicament, thus plainly and expressly encompasses the species of claim 33, drawn to a making of a gene therapy medicament.

Art Unit: 1632

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

/Mark L. Shibuya, Ph.D./
Primary Examiner, Art Unit 1639

Conferees:

/JD Schultz, PhD/
Supervisory Patent Examiner, Art Unit 1635

/Peter Paras, Jr./
Supervisory Patent Examiner, Art Unit 1632